Mucopolysaccharides: Functions, Types, and Disorders

Mucopolysaccharides, now more commonly called glycosaminoglycans (GAGs), are long sugar chains that form a critical part of connective tissues throughout the body. They help cushion joints, maintain skin elasticity, support cell signaling, and regulate how tissues develop and repair. When the body cannot properly break them down, the buildup causes a family of serious inherited disorders called mucopolysaccharidoses. The term “acid mucopolysaccharides” dominated medical literature for decades before being renamed glycosaminoglycans in the late twentieth century, but both terms still circulate, and the diseases they cause still carry the older name.

What Mucopolysaccharides Actually Are

Mucopolysaccharides are repeating chains of sugar molecules, often attached to a protein core to form larger structures called proteoglycans. They sit in the spaces between cells and on cell surfaces, where they interact with water, proteins, and signaling molecules. Their ability to attract and hold water is what gives cartilage its shock-absorbing quality and keeps skin plump. Different types of GAGs have different structures and cluster in different tissues, but they all share this basic architecture of repeating sugar units, many of which carry sulfate groups that give them a strong negative charge.

The observation that these sugar chains appeared in both mucus and polysaccharides led to the original name “mucopolysaccharides.” After the first clinical description of what we now recognize as a mucopolysaccharidosis patient was made in 1917, it took several more decades before researchers linked the presence of acid mucopolysaccharides in urine and tissues to a distinct group of diseases. In the late 1960s, the cause was pinpointed: defects in the breakdown of GAGs. The specific enzyme deficiencies for all eleven types and subtypes of MPS were identified in the years that followed, and the genes responsible have since been mapped.¹

The Major Types and Where They Live

There are several principal types of GAGs, each with a preferred tissue home and a somewhat different biological role. Knowing which types exist helps make sense of why different enzyme deficiencies cause different patterns of disease.

• Heparan sulfate: found on cell surfaces and in the extracellular matrix of most tissues, especially the liver, lungs, and blood vessels. It plays an outsized role in cell signaling and growth factor regulation.
• Dermatan sulfate: concentrated in skin, blood vessels, heart valves, and tendons. It contributes to tissue elasticity and wound repair.
• Chondroitin sulfate: the dominant GAG in cartilage and bone. It helps cartilage resist compression and contributes to joint health.
• Keratan sulfate: found mainly in cartilage, the cornea, and intervertebral discs. It plays a structural role in maintaining transparent corneal tissue and cushioning spinal segments.
• Hyaluronic acid (hyaluronan): unique among GAGs because it is not sulfated and is not attached to a protein core. It is abundant in synovial fluid, the vitreous humor of the eye, and skin.

These GAGs do not work in isolation. In collagen-rich tissues, for example, chondroitin sulfate, dermatan sulfate, and hyaluronic acid each alter the physical properties of the surrounding matrix in different ways, affecting stiffness, how easily fluid flows through the tissue, and the size of pores in the collagen network.² This means that even subtle shifts in GAG composition can change how a tissue behaves mechanically.

How They Function in the Body

The biological roles of mucopolysaccharides go well beyond padding and lubrication. They are active participants in signaling, blood clotting, and tissue development.

Lubrication and Shock Absorption

Hyaluronic acid is the poster molecule for this function. Solutions of hyaluronic acid can be extremely viscous and behave in ways that shift depending on how fast they are being pushed around. At low movement speeds, the fluid is thick and cushioning; at high speeds, it thins and allows joints to glide. This behavior depends on the molecule’s concentration and its very high molecular weight, and it directly affects how well synovial fluid lubricates your joints.³ Chondroitin sulfate and keratan sulfate serve a complementary role in cartilage, helping it spring back after being compressed during movement.

Cell Signaling and Development

Heparan sulfate proteoglycans on cell surfaces act as a kind of switchboard for growth signals. They help organize how cells receive instructions from growth factors, morphogens, and other signaling molecules during embryonic development and throughout adult life. Among the pathways they regulate are ones essential for limb formation, brain patterning, and wound healing.⁴ In cancer biology, this same signaling-hub behavior becomes a liability: heparan sulfate proteoglycans on tumor cells can hijack growth factor and inflammatory pathways to promote tumor growth and spread.⁵

Blood Clotting Regulation

Heparan sulfate is also integral to preventing inappropriate blood clotting. The anticoagulant drug heparin is actually a highly sulfated form of heparan sulfate, originally derived from animal tissues. Heparin works by dramatically boosting the activity of antithrombin, a natural protein that shuts down clotting enzymes. It does this through both a shape change in antithrombin and a bridging mechanism that brings antithrombin and its target protease together.⁶ Your own blood vessel walls are lined with heparan sulfate that performs a milder version of the same trick, keeping blood flowing smoothly past the vessel lining.

What Happens When GAG Breakdown Fails

Every day, your cells recycle worn-out GAG molecules inside small compartments called lysosomes. This recycling requires a chain of enzymes, each responsible for clipping off one specific piece of the sugar chain. If any single enzyme in that chain is missing or defective, partially broken-down GAGs pile up inside lysosomes, eventually damaging cells, tissues, and organs. These buildup diseases are the mucopolysaccharidoses.⁷

For a long time, researchers assumed the GAG accumulation itself was the whole problem: lysosomes swelling up with undigested material until cells simply could not function. That picture turned out to be incomplete. The stored GAGs also disrupt many other cellular processes, triggering inflammation, disturbing calcium signaling, and interfering with autophagy (the cell’s general cleanup system).⁸ This broader cellular havoc helps explain why MPS disorders affect so many organ systems and why treatments that merely reduce storage levels do not always resolve symptoms.

Because connective tissue is found almost everywhere in the body, MPS disorders tend to involve many organs simultaneously, with bones, cartilage, and connective tissues typically hit hardest.⁹

The Seven Mucopolysaccharidoses

Eleven enzyme deficiencies produce seven recognized MPS types (some types have subtypes based on which of several enzymes in the same pathway is affected). All are inherited, and all are rare individually, though collectively they affect roughly one in every 25,000 births. Each type has a traditional eponym, a Roman numeral designation, and a particular GAG or set of GAGs that accumulates.

MPS I — Hurler, Hurler-Scheie, and Scheie Syndromes

MPS I is caused by a deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of heparan sulfate and dermatan sulfate.¹⁰ The severe form, Hurler syndrome, causes coarsened facial features, skeletal deformities, organ enlargement, corneal clouding, and progressive intellectual disability. The milder Scheie form may cause stiff joints and heart valve problems without affecting cognition as heavily. Between these lies Hurler-Scheie, with intermediate severity. A single common mutation, a stop codon at position 402 of the iduronidase protein, accounts for roughly a third of MPS I disease alleles and is associated with the most severe phenotype when present on both chromosomes. Patients who carry that mutation on only one chromosome alongside a different mutation can show a wide range of clinical severity.¹¹

MPS II — Hunter Syndrome

Hunter syndrome results from mutations in the gene encoding iduronate-2-sulfatase, an enzyme needed for the breakdown of dermatan sulfate and heparan sulfate.¹² It is the only MPS that is X-linked, meaning it overwhelmingly affects boys. The severe form typically presents in early childhood with thick skin, short neck, widely spaced teeth, hearing loss, heart valve disease, and progressive cognitive decline. Some patients have a milder course without significant brain involvement.¹³ The accumulation of GAGs leads to both systemic and central nervous system symptoms.¹⁴

MPS III — Sanfilippo Syndrome

Sanfilippo syndrome stands out among the MPS types because its most devastating effects are neurological rather than skeletal. It is caused by a deficiency in one of several enzymes involved exclusively in heparan sulfate degradation, giving rise to subtypes A through E.¹⁵ Children with Sanfilippo typically develop normally in their first years, then begin to show progressive cognitive decline and severe hyperactivity that does not respond to stimulant medications. Physical features are relatively mild compared to other MPS types, which is why it is frequently misdiagnosed initially as autism, ADHD, or unexplained developmental delay.¹⁶

MPS IV — Morquio Syndrome

Morquio syndrome type A is caused by deficiency of the enzyme N-acetylgalactosamine-6-sulfate sulfatase, which is responsible for breaking down keratan sulfate and chondroitin 6-sulfate. Because those GAGs are concentrated in cartilage and bone, the hallmark of Morquio is skeletal dysplasia: short stature, spinal instability, knock-knees, and severely reduced bone mineral density. In one study, average bone density Z-scores were around −2 across the whole body and as low as −5 in the spine, with patients who could still walk independently showing somewhat better numbers.¹⁷ Intelligence is typically preserved, which distinguishes Morquio from most other MPS types.

Other MPS Types

MPS VI (Maroteaux-Lamy syndrome) involves dermatan sulfate accumulation, causing skeletal and cardiac problems without cognitive decline. MPS VII (Sly syndrome) is extremely rare and involves the accumulation of several GAGs at once due to a deficiency in beta-glucuronidase. MPS IX, the rarest of all, involves hyaluronic acid accumulation and causes joint and soft tissue masses. Each type maps to a specific broken step in the GAG recycling chain, and the pattern of which tissues are most affected follows logically from which GAGs pile up.

Diagnosing MPS Disorders

Diagnosis has traditionally followed a stepwise path. When a clinician suspects MPS based on physical signs, the first test is usually measuring GAG levels in the urine, which are elevated in most types. If that screen is positive, specific enzyme activity assays confirm which enzyme is deficient. Genetic testing then identifies the exact mutation. There is an increasing trend, however, toward putting genetic testing earlier in the investigation, sometimes even first, which can speed up diagnosis and provide clearer prognostic information.¹⁸

Newborn screening for MPS is an area of active expansion. Multiplex enzyme assays using tandem mass spectrometry can now test for several MPS types simultaneously from a single dried blood spot, with a run time of about two minutes per sample. These assays can clearly separate healthy infants from affected children, and their analytical ranges are large enough to be reliable.¹⁹ Several countries and U.S. states have added one or more MPS types to their newborn screening panels, since earlier treatment generally leads to better outcomes. The diagnostic picture can also be complicated by related conditions like mucolipidosis II and III, which share some clinical features with MPS but involve a different mechanism: a failure of the enzyme-tagging system that routes lysosomal enzymes to their proper destination, rather than a deficiency in the enzymes themselves.²⁰

Current Treatment Strategies

No cure exists for any MPS type, but two main approaches can slow disease progression: enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT).

ERT involves regular intravenous infusions of the missing enzyme. It works reasonably well for peripheral organs: liver size decreases, urine GAG levels drop, and joint mobility can improve. The major limitation is the brain. The blood-brain barrier blocks these large enzyme molecules from reaching the central nervous system, so ERT does little for the neurological features of MPS types that affect cognition.²¹ Animal studies have confirmed this frustrating split: intravenous enzyme replacement reduced GAG levels in peripheral tissues but failed to lower them in the brain.²²

HSCT, typically using donor bone marrow or cord blood, takes a different approach. Transplanted donor cells take up residence in the body and produce the missing enzyme on an ongoing basis. Some of these donor-derived cells can cross into the brain, making HSCT the current standard of care for severe MPS I (Hurler syndrome), where it prolongs survival, slows neurological decline, and reduces the progression of organ involvement.²³ HSCT has also been used in selected patients with MPS II, IVA, VI, and VII, though transplant outcomes and long-term disease-specific results vary across types. Improved conditioning regimens and better donor matching have significantly reduced transplant-related deaths and graft failure over the past two decades.²⁴ Even so, significant motor and sensory handicaps often persist after transplant, and skeletal disease in particular tends to progress despite successful engraftment.

The next frontier is gene therapy. Researchers are exploring ways to combine stem cell transplantation with gene correction so that engrafted cells produce enzyme at higher-than-normal levels, potentially delivering enough enzyme to reach the brain. Brain-targeted approaches, including engineered enzymes designed to cross the blood-brain barrier and direct intrathecal delivery (injection into the spinal fluid), are in various stages of preclinical and early clinical testing.²⁵

GAGs Across the Animal Kingdom

Mucopolysaccharides are not unique to mammals. A comparative survey of GAGs across eleven invertebrate phyla found that heparan sulfate, in particular, appears in organisms ranging from very primitive animals to humans, indicating that its signaling functions are ancient and fundamental. Chondroitin and dermatan sulfate in lower organisms tend to have simpler structures and more specialized roles. Hyaluronic acid, interestingly, has been reported outside vertebrates only in one group: mollusks.²⁶ The deep evolutionary conservation of heparan sulfate underscores just how central these molecules are to animal biology. It also means that animal models of MPS, from mice to dogs, replicate the human diseases fairly well, which has been invaluable for developing and testing therapies.

Hyaluronic Acid in Medicine and Industry

While most GAGs are discussed in clinical contexts when they accumulate pathologically, hyaluronic acid has had a separate and remarkable career as a biomaterial. Its ability to hold water, gel easily, and integrate with living tissue without provoking strong immune reactions has made it a workhorse in cosmetic dermatology (injectable fillers), ophthalmology (surgical aids), and orthopedics (viscosupplementation for arthritic joints).

Beyond these familiar uses, hyaluronic acid is being engineered into hydrogels for tissue engineering. By chemically crosslinking hyaluronic acid chains, researchers can create scaffolds with tunable mechanical properties, controlled biodegradation, and good compatibility with living cells.²⁷ These hydrogels are being explored as injectable cell scaffolds, drug delivery platforms, and wound healing aids.²⁸ Other crosslinking chemistries have produced hyaluronic acid gels shown to be compatible with soft tissue engineering applications.²⁹ The irony is that the same molecule whose accumulation causes disease when it cannot be degraded is, when harnessed properly, one of the most promising building blocks in regenerative medicine.